Johnson and Johnson 2008 Annual Report Download - page 57

Download and view the complete annual report

Please find page 57 of the 2008 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

11. Segments of Business(1) and Geographic Areas
Sales to Customers(2)
____________________________________
(Dollars in Millions) 2008 2007 2006
Consumer —
United States $ 6,937 6,408 4,573
International 9,117 8,085 5,201
Total 16,054 14,493 9,774
Pharmaceutical —
United States 14,831 15,603 15,092
International 9,736 9,263 8,175
Total 24,567 24,866 23,267
Medical Devices and Diagnostics—
United States 10,541 10,433 10,110
International 12,585 11,303 10,173
Total 23,126 21,736 20,283
Worldwide total $63,747 61,095 53,324
Operating Profit Identifiable Assets
____________________________________ ____________________________________
(Dollars in Millions) 2008(5) 2007(6) 2006(7) 2008 2007 2006
Consumer $ 2,674 2,277 1,374 $23,765 26,550 25,380
Pharmaceutical 7,605 6,540 6,894 19,544 19,780 18,799
Medical Devices and Diagnostics 7,223 4,846 6,126 20,779 19,978 18,601
Total 17,502 13,663 14,394 64,088 66,308 62,780
Less: (Income) Expense not allocated to segments(3) 573 380 (193)
General corporate(4) 20,824 14,646 7,776
Worldwide total $16,929 13,283 14,587 $84,912 80,954 70,556
Additions to Property, Depreciation and
Plant & Equipment Amortization
____________________________________ ____________________________________
(Dollars in Millions) 2008 2007 2006 2008 2007 2006
Consumer $ 499 504 344 $ 489 472 255
Pharmaceutical 920 1,137 1,246 986 1,033 929
Medical Devices and Diagnostics 1,251 919 823 1,146 1,080 861
Segments total 2,670 2,560 2,413 2,621 2,585 2,045
General corporate 396 382 253 211 192 132
Worldwide total $3,066 2,942 2,666 $2,832 2,777 2,177
Sales toCustomers(2) Long-Lived Assets(8)
____________________________________ ____________________________________
(Dollars in Millions) 2008 2007 2006 2008 2007 2006
United States $32,309 32,444 29,775 $21,674 21,685 22,432
Europe 16,782 15,644 12,786 14,375 15,578 14,443
Western Hemisphere excluding U.S. 5,173 4,681 3,542 3,328 3,722 3,108
Asia-Pacific, Africa 9,483 8,326 7,221 1,898 1,261 1,206
Segments total 63,747 61,095 53,324 41,275 42,246 41,189
General corporate 785 702 543
Other non long-lived assets 42,852 38,006 28,824
Worldwide total $63,747 61,095 53,324 $84,912 80,954 70,556
(1) See Note 1 for a description of the segments in which the Company operates.
(2) Export sales are not significant. In 2008, 2007 and 2006, the Company did not have a customer that represented 10% of total revenues.
(3) Amounts not allocated to segments include interest (income) expense, minority interest and general corporate (income) expense.
(4) General corporate includes cash and marketable securities.
(5) Includes $7 million and $174million of In-Process Research and Development (IPR&D) for the Consumer and Medical Devices and Diagnostics segments, respectively. Includes $379 million
of fourth quarter net litigation gain, comprised of a $50 million expense in the Consumer segment and a gain of $429 million in the Medical Devices and Diagnostics segment. The Medical
Devices and Diagnostics segment also includes $536 million gain on the divestiture of the Professional Wound Care business of Ethicon, Inc.
(6) Includes $745million of restructuring expense, comprised of $15 million, $429 million, and $301 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics segments,
respectively. The Medical Devices and Diagnostics segment includes $807 million of IPR&D. The Pharmaceutical segment also includes $678 million for the write-down of the NATRECOR®
intangible asset.
(7) Includes $320 million and $239 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also
includes the Guidant acquisition agreement termination fee, less associated expenses, of $622 million.
(8) Long-lived assets include property, plant and equipment, net for 2008, 2007 and 2006 of $14,365, $14,185 and $13,044, respectively, and intangible assets and goodwill, net for 2008,
2007 and 2006 of $27,695, $28,763 and $28,688, respectively.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 55